Market Place
Sourcing Support
Pardes Biosciences Announces Closing of Tender Offer
31 Aug 2023 //
GLOBENEWSWIRE
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Pardes
28 Aug 2023 //
BUSINESSWIRE
Pardes changes hands (sort of) in wake of COVID-19 trial fail
17 Jul 2023 //
FIERCE BIOTECH
Pardes Bio to suspend COVID-19 drug development after mid-stage trial fails
04 Apr 2023 //
REUTERS
Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
Pardes Biosciences to Present at SVB Securities Global Biopharma Conference
01 Feb 2023 //
GLOBENEWSWIRE
Pardes Biosciences Reports 3Q 2022 Financial Results and Provides Business
07 Nov 2022 //
GLOBENEWSWIRE
Pardes Biosciences to Present at Jefferies London Healthcare Conference
01 Nov 2022 //
GLOBENEWSWIRE
Pardes initiates Phase II trial of Covid-19 antiviral drug
14 Sep 2022 //
CLINICALTRIALSARENA
Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451
13 Sep 2022 //
GLOBENEWSWIRE
Pardes Biosciences to Present at the H.C. Wainwright 24th Global Conference
12 Sep 2022 //
GLOBENEWSWIRE
Pardes Biosciences Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Pardes Biosciences to Present at Jefferies Global Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Pardes Biosciences Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Pardes Biosciences Reports Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
Pardes Bio to Present at International Conference On Antiviral Research 2022
21 Mar 2022 //
GLOBENEWSWIRE
Pardes snags ex-Dermira CEO Wiggans to lead COVID-19 antiviral
05 Mar 2022 //
FIERCEBIOTECH
Pardes Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Mar 2022 //
GLOBENEWSWIRE
Pardes Biosciences to Present at Cowen Healthcare Conference
03 Mar 2022 //
GLOBENEWSWIRE
Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board
02 Mar 2022 //
GLOBENEWSWIRE
Pardes Biosciences Presents Interim Data from Ongoing PBI-0451 Phase 1 Trial
14 Feb 2022 //
GLOBENEWSWIRE
Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial
08 Feb 2022 //
GLOBENEWSWIRE
FDA clears Pardes’ IND application for oral Covid-19 antiviral drug
03 Feb 2022 //
PHARMACEUTICAL-TECHNOLOGY
Pardes Bio Debuts as Publicly Traded Company Focused on Oral Antiviral Therapies
27 Dec 2021 //
GLOBENEWSWIRE
FSII, Pardes Parter to Tackle COVID-19 via an Oral Antiviral
21 Dec 2021 //
BUSINESSWIRE
Pardes Biosciences Initiates Human Trial for PBI-0451 in SARS-CoV-2
26 Aug 2021 //
GLOBENEWSWIRE
Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to BOD
05 Aug 2021 //
GLOBENEWSWIRE
